Categories
CPIP Roundup

[Archived Post] CPIP Roundup – April 30, 2020

Greetings from CPIP Executive Director Sean O’Connor As we move into another month of stay-at-home here in the DMV—and perhaps some re-openings—we here at CPIP hope that you and yours are staying safe and healthy while we weather this crisis. We continue to move forward, however. Our biggest news this month is the addition of […]

Categories
C-IP2 News

[Archived Post] CPIP Welcomes Joshua Kresh as Deputy Director

CPIP is proud to welcome Joshua Kresh to our leadership team! As Deputy Director, Joshua will report to CPIP Executive Director Sean O’Connor while managing and participating in CPIP’s day-to-day operations. Joshua will oversee CPIP’s academic research, policy, and fundraising efforts, working as well on planning and executing CPIP events such as conferences, meetings, fellowships, […]

Categories
C-IP2 News

[Archived Post] CPIP Bids a Fond Farewell to Kevin Madigan and Seeks New Deputy Director

Longtime CPIP staff member Kevin Madigan is leaving the Center next week to become VP, Legal Policy and Copyright Counsel at the Copyright Alliance. “I joined CPIP just over four years ago, and my time with the Center and Scalia Law has been rewarding on so many levels. The knowledge I’ve gained and the relationships […]

Categories
CPIP Roundup

[Archived Post] CPIP Roundup – August 29, 2019

Greetings from CPIP Executive Director Sean O’Connor With a new academic year beginning at Antonin Scalia Law School, the CPIP team continues to build on a productive summer of scholarship, events, and more. Our WIPO-CPIP Summer School on Intellectual Property this past June boasted 70 students from 30 countries for a two-week crash course on […]

Categories
Biotech Patents Pharma

[Archived Post] “No Combination Drug Patents Act” Stalls, but Threats to Innovation Remain

By Kevin Madigan & Sean O’Connor This week, the Senate Judiciary Committee was to mark up a bill limiting patent eligibility for combination drug patents—new forms, uses, and administrations of FDA approved medicines. While the impetus was to curb so-called “evergreening” of drug patents, the effect would have been to stifle life-saving therapeutic innovations. Though […]

Categories
FTC Innovation

[Archived Post] CPIP Scholars Join Comment Letter to FTC Supporting Evidence-Based Approach to IP Policymaking

On December 21, 2018, CPIP Senior Scholars Jonathan Barnett, Chris Holman, Erika Lietzan, Adam Mossoff, Sean O’Connor, and Kristen Osenga joined a comment letter that was filed with the FTC as part of its ongoing hearings on Competition and Consumer Protection in the 21st Century. The comment letter was joined by 18 legal academics, economists, […]

Categories
Patent Law Patent Theory

[Archived Post] Proposed Misuse of Section 1498 Relies on the False Claim that Patents Are Not Property

By Kathleen Wills* The question whether patents are property rights is a continuing and hotly debated topic in IP law. Despite an abundance of scholarship (see here, here, here, here, and here) detailing how intellectual property (“IP”) rights have long been equated with property rights in land and other tangible assets, critics often claim that […]

Categories
Innovation Patent Law

[Archived Post] Proposal for Drug Price Controls is Legally Unprecedented and Threatens Medical Innovation

By Adam Mossoff, Sean O’Connor, & Evan Moore* The price of the miracle drugs everyone uses today is cause for concern among people today. The President has commented on it. Some academics, lawyers, and policymakers have routinely called for the government to “do something” to lower prices. The high prices are unsurprising: cutting-edge medical treatments are […]

Categories
Press Release

[Archived Post] CPIP Announces Leadership Transitions

ARLINGTON, Virginia – August 22, 2018 – The Center for the Protection of Intellectual Property (CPIP) announced today that Matthew Barblan, CPIP’s Executive Director, will leave the center this month to join the Association of American Publishers (AAP) as Vice President, Public Policy. “It has been an amazing journey working with such wonderful colleagues to […]

Categories
Copyright Copyright Licensing Copyright Theory Infringement Intellectual Property Theory Internet Reasonable Royalty Uncategorized

[Archived Post] Despite What You Hear, Notice and Takedown is Failing Creators and Copyright Owners

In a recent op-ed in the LA Times, Professors Chris Sprigman and Mark Lemley praise the notice and takedown provisions of the Digital Millennium Copyright Act (DMCA) as “a bit of copyright law worth saving.” They argue that Section 512 of the DMCA continues to serve its purpose of balancing the rights of copyright owners […]